The current phase 3 trial is for people with ALS. It is full and due to complete at the end of August. The early phase results looked good and anecdotally people say they are seeing stabilization , slowing or even improvements. They are going to do a presymptomatic trial and we are expecting it to enroll soon.
the biogen c9 trial is the same technology IF it has similar results they plan a presymptomatic trial for C9 IF they have reliable biomarkers. The neurofilament they are using for sod1 may not be a reliable for c9. This is why carriers need to be in studies